This technology is a pharmaceutical composition for preventing and treating chronic pain, containing as an active ingredient the beta-amyloid peptide of SEQ ID NO: 1, a polynucleotide encoding it, or an expression vector containing said polynucleotide. It targets neuropathic pain induced by central nervous system injury and also includes health functional food compositions using the same active ingredient.
Neuropathic pain is a chronic condition caused by nerve damage or nervous system dysfunction, characterized by allodynia, hyperalgesia, and spontaneous burning sensations that can persist for years. Clinical treatments like anticonvulsants (carbamazepine, gabapentin) and opioids often fail to provide sufficient relief, require repeated dosing with significant side effects, and morphine specifically carries risks of tolerance and fatal overdose. Meanwhile, the physiological function of beta-amyloid, known primarily as a cause of dementia, has remained unclear, leaving it unexplored for pain therapy.
This technology is based on the discovery that elevated neural activity and associated pain following nerve injury can be regulated by beta-amyloid administration. Unlike conventional methods that temporarily block calcium ion channels or TRPV1/TRPA1, this approach corrects hypersensitive pain processing by normalizing synaptic plasticity. Gene delivery can utilize viral vectors such as AAV1–AAV16 serotype adeno-associated viruses or lentiviruses, or non-viral vectors like nanoparticles, exosomes, liposomes, or plasmids. Applicable to treating pain from spinal cord injury, multiple sclerosis, post-stroke central pain, and diabetic neuropathy, it offers the potential for long-term pain control via gene therapy, replacing the need for repeated doses of traditional analgesics.
WO2022-169211A1
